Betting on ‘Golden Age’ of Colonoscopies, Investors Buy Up Gastroenterology Practices
In 2021, the number of private equity acquisitions of gastroenterology practices grew by 28% over the previous year, according to Spherix Global Insights and Fraser Healthcare. Complex government regulations, technological innovations, and insurance industry practices have driven many gastroenterologists to sell shares in their practices, said Praveen Suthrum, who runs a consulting company for physician […]
Eylea Keeps its Lead In the Retinal Space as Physicians Remain Hesitant on Roche’s Susvimo — Report
Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting it as a more manageable option for patients with wet age-related macular degeneration. However, safety concerns leave some physicians hesitant. While most ophthalmologists have heard of Susvimo — 86%, according to the latest Spherix survey […]
Spherix Global Insights Finds US Primary Biliary Cholangitis Market Poised for Transformation as Pipeline Therapies Progress in Clinical Development
Four pipeline product profiles were evaluated by US gastroenterologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., March 16, 2022 /PRNewswire/ — Spherix recently surveyed 107 US gastroenterologists and conducted ten qualitative interviews (including a key opinion leader and six clinical trial participants) to assess the current and future management of primary biliary cholangitis (PBC). The […]
Gastroenterologists Report Challenges Treating Eosinophilic Esophagitis as New Therapies Inch Closer to FDA Approval
A high percentage of undiagnosed patients and difficulties with treatment adherence among this mostly younger male patient population could be addressed by the entrance of one or more FDA-approved therapies in the next year EXTON, Pa., November 16, 2021 /PRNewswire/ — Spherix recently surveyed 101 US gastroenterologists and followed up with ten qualitative interviews (including four with […]
Increased Biosimilar Prescribing and New Subcutaneous Formulations Are Poised to Impact Biologic Switching in the EU Inflammatory Bowel Disease Market, According to Spherix Global Insights
Infliximab and adalimumab biosimilars continue to increase their presence in ulcerative colitis and Crohn’s disease therapy switching, while Entyvio SC and Remsima SC will cannibalize prescribing of their intravenous formulations EXTON, Pa., November 9, 2020 /PRNewswire/ — According to the latest report published as part of Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU gastroenterologists […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
Takeda’s Entyvio Defends Share Against Janssen’s Stelara in the Crohn’s Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer’s Xeljanz Secures an FDA Win
According to a new report by Spherix Global Insights, Janssen’s Remicade is taking a dual hit from the expansion of alternative mechanism of action biologics such as Entyvio and Stelara as well as the slow, but growing, adoption of infliximab biosimilars in the IBD market Download Report Overview EXTON, Pa. Nov. 21, 2017 /PRNewswire/ — […]
RealTime Dynamix™: Crohn’s Disease US Q2
Crohn’s Disease (CD) is a common form of inflammatory bowel diseases, currently affecting the lives of approximately 700,000 Americans. Theintroduction of biologics has changed the face of treatment for moderateto-severe CD patients. However, recent launches, an active pipeline, and the imminent introduction of biosimilars present an opportunity for major future shifts in the CD landscape. […]
The Battle for Preferred Alternative Mechanism Biologic in Crohn’s Disease Heats Up as Launch of Janssen’s Stelara Approaches the Six-Month Mark
While gastroenterologists report a strong intent to increase future prescribing, they are quite divided about whether Stelara will displace Takeda’s Entyvio as the alternate mechanism share leader, according to the latest report by Spherix Global Insights Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Spherix Global Insights has released “RealTime Dynamix: Crohn’s Disease, Q1 […]
